Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
sodium nitrite + citric acid
- Development stage
- Phase 2
- Lead developer
- University of Aberdeen
- Modality
- Small Molecules
- Administration
- Topical
01
Overview
This topical nitric oxide treatment, developed by researchers at the University of Aberdeen, is a combination therapy for anogenital warts. It consists of two separate creams containing sodium nitrite (up to 6%) and citric acid (up to 9%) that, when co-applied, react to produce nitric oxide (NO). Nitric oxide acts as the active agent with antiviral and antimicrobial properties. A Phase 2 clinical trial demonstrated that a high-dose regimen (6% sodium nitrite and 9% citric acid applied twice daily) achieved a 31% complete clearance rate of warts at 12 weeks. The development was supported by ProStrakan and Origin Pharmaceuticals.
- Other names
- acidified nitritetopical nitric oxidetopical NO
Beyond the preview
Go deeper on sodium nitrite + citric acid.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on sodium nitrite + citric acid.